

SmartPA Criteria Proposal

Drug/Drug Class:	Direct Renin Inhibitors and Combinations PDL Edit
First Implementation Date:	April 9, 2008
Revised Date:	January 21, 2021
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Direct renin inhibitors directly target the renin-angiotensin-aldosterone system (RAAS) at the point of activation by inhibiting renin and blocking the conversion of angiotensinogen to angiotensin I, leading to decreased plasma renin activity. Tekturma® (aliskiren) is the only approved product in this therapeutic class. During Tekturma therapy the effects of increased renin levels are blocked, so that plasma renin activity, (inactive) angiotensin I, and (active) angiotensin II are all reduced. Angiotensin II, a powerful vasoconstrictor, also inhibits renin release, thus providing a negative feedback to the RAAS system. Aliskiren is metabolized by CYP3A4. Drug interactions have been noted with co-administration of Avapro, Lipitor, ketoconazole, and furosemide. Tekturma offers an alternative in the treatment of hypertension, but at this time doesn't offer an advantage over the proven efficacy of existing angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) classes.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Aliskiren Tekturma HCT® 	<ul style="list-style-type: none"> Tekturma®

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Direct Renin Inhibitors and Combinations
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 or more Angiotensin Receptor Blocker (ARB) agents
- Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Drug Effectiveness Review Project – Drug Class Review on DRI, AIIRA, ACEI. Center for Evidence-Based Policy, Oregon Health & Science University; January 2010/Updated September 2015
2. Evidence-Based Medicine and Fiscal Analysis: "Direct Renin Inhibitors and Combination Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2020.
3. Evidence-Based Medicine Analysis: "Direct Renin Inhibitors and Combinations", UMKC-DIC; July 2020.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
5. USPDI, Micromedex; 2020.
6. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.